|
it would limit coverage of the company’s top-sellingdrug, is in discussions with the insurer and doesn’t expect thedecision to hurt business, executives told investors.“We do not expect the bulletin to have a material adverseimpact,” Chief Executive Officer Don Bailey said today on aconference call. Reimbursement decisions are made on a case-by-case basis, he said.Aetna, the third-biggest U.S. health...
|
